-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On October 12, the CDE official website showed that the clinical trial application of Ou Kangweishi OT202 eye drops was approved by the Food and Drug Administration for the first time for the treatment of dry eye
Dry eye is a chronic ocular surface disease caused by multiple factors.
The key treatment for dry eye is to break the vicious circle of inflammation
OT202 eye drops is a tyrosine kinase inhibitor independently developed by Okvision.
Source: Ou Kangweishi official website
At present, Ou Kangweishi has 4 dry eye drugs under development, namely OT-202, OT-204, OT-503, and OT-1301